688443 智翔金泰-U
已收盘 10-30 15:00:00
资讯
新帖
简况
智翔金泰（688443）披露2026年第三季度报告，10月30日股价上涨1.18%
证券之星 · 10-30 22:59
智翔金泰（688443）披露2026年第三季度报告，10月30日股价上涨1.18%
智翔金泰：第三季度净利3.1亿元 同比扭亏为盈
格隆汇 · 10-30 20:58
智翔金泰：第三季度净利3.1亿元 同比扭亏为盈
智翔金泰(688443)9月30日股东户数1.25万户，较上期减少5.42%
证券之星 · 10-30 19:13
智翔金泰(688443)9月30日股东户数1.25万户，较上期减少5.42%
智翔金泰(688443.SH)发布前三季度业绩，归母净亏损638.35万元
智通财经 · 10-30 17:18
智翔金泰(688443.SH)发布前三季度业绩，归母净亏损638.35万元
智翔金泰（688443）10月27日主力资金净买入285.31万元
证券之星 · 10-28 08:47
智翔金泰（688443）10月27日主力资金净买入285.31万元
智翔金泰（688443）10月23日主力资金净买入171.34万元
证券之星 · 10-24
智翔金泰（688443）10月23日主力资金净买入171.34万元
智翔金泰：泰利奇拜单抗注射液慢性自发性荨麻疹适应症上市申请获受理
证券之星 · 10-23
智翔金泰：泰利奇拜单抗注射液慢性自发性荨麻疹适应症上市申请获受理
智翔金泰：泰利奇拜单抗注射液慢性鼻窦炎伴鼻息肉适应症上市申请获受理
证券之星 · 10-14
智翔金泰：泰利奇拜单抗注射液慢性鼻窦炎伴鼻息肉适应症上市申请获受理
智翔金泰（688443）10月13日主力资金净买入60.90万元
证券之星 · 10-14
智翔金泰（688443）10月13日主力资金净买入60.90万元
智翔金泰（688443）披露变更签字注册会计师公告，10月9日股价下跌2.35%
证券之星 · 10-09
智翔金泰（688443）披露变更签字注册会计师公告，10月9日股价下跌2.35%
股市必读：智翔金泰（688443）9月30日董秘有最新回复
证券之星 · 10-08
股市必读：智翔金泰（688443）9月30日董秘有最新回复
股市必读：智翔金泰（688443）9月24日董秘有最新回复
证券之星 · 09-28
股市必读：智翔金泰（688443）9月24日董秘有最新回复
股市必读：智翔金泰（688443）9月4日董秘有最新回复
证券之星 · 09-07
股市必读：智翔金泰（688443）9月4日董秘有最新回复
每周股票复盘：智翔金泰（688443）营收增237.29%
证券之星 · 09-06
每周股票复盘：智翔金泰（688443）营收增237.29%
智翔金泰（688443）披露2026年半年度报告，8月31日股价下跌2.23%
证券之星 · 08-31
智翔金泰（688443）披露2026年半年度报告，8月31日股价下跌2.23%
智翔金泰2026年半年报：核心产品放量营收翻倍，亏损幅度扩大
蓝鲸财经 · 08-31
智翔金泰2026年半年报：核心产品放量营收翻倍，亏损幅度扩大
智翔金泰(688443)6月30日股东户数1.32万户，较上期增加2.84%
证券之星 · 08-30
智翔金泰(688443)6月30日股东户数1.32万户，较上期增加2.84%
每周股票复盘：智翔金泰（688443）纬利妥米单抗附条件获批上市
证券之星 · 08-30
每周股票复盘：智翔金泰（688443）纬利妥米单抗附条件获批上市
智翔金泰：纬利妥米单抗注射液获附条件批准上市
证券之星 · 08-27
智翔金泰：纬利妥米单抗注射液获附条件批准上市
每周股票复盘：智翔金泰（688443）GR2302注射液获两项临床试验批准
证券之星 · 08-23
每周股票复盘：智翔金泰（688443）GR2302注射液获两项临床试验批准
加载更多
公司概况
公司名称：
重庆智翔金泰生物制药股份有限公司
所属行业：
医药制造业
上市日期：
2023-06-20
主营业务：
重庆智翔金泰生物制药股份有限公司的主营业务是抗体药物的研发、生产及商业化。公司的主要产品是赛立奇单抗（GR1501）、斯乐韦米单抗（GR1801）、纬利妥米单抗（GR1803）、唯康度塔单抗（GR2001）、泰利奇拜单抗（GR1802）、GR1603、GR2301、GR2303、GR2302、GR2304、GR2502、GR2603。公司2022年11月28日获得高新技术企业认定证书。
发行价格：
37.88
{"stockData":{"symbol":"688443","market":"SH","secType":"STK","nameCN":"智翔金泰-U","latestPrice":23.13,"timestamp":1793343600000,"preClose":22.86,"halted":0,"volume":3242754,"delay":0,"changeRate":0.0118,"floatShares":143000000,"shares":367000000,"eps":-0.5712,"marketStatus":"已收盘","change":0.27,"latestTime":"10-30 15:00:00","open":22.95,"high":24.36,"low":22.41,"amount":75467300,"amplitude":0.0853,"askPrice":23.13,"askSize":190,"bidPrice":23.11,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-0.5712,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1793583000000},"marketStatusCode":5,"adr":0,"adjPreClose":22.86,"symbolType":"stock_kcb","openAndCloseTimeList":[[1793323800000,1793331000000],[1793336400000,1793343600000]],"highLimit":25.15,"lowLimit":20.57,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":366680000,"isCdr":false,"pbRate":6.62,"roa":"--","roe":"--","epsLYR":-1.46,"committee":-0.092593,"marketValue":8481000000,"turnoverRate":0.0226,"status":0,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-11-02。","afterMarket":{"amount":0,"volume":0,"close":23.13,"buyVolume":1800,"sellVolume":0,"time":1793345637746,"indexStatus":"已收盘 10-30 15:30:00","preClose":22.86},"floatMarketCap":3317000000},"requestUrl":"/m/hq/s/688443/","defaultTab":"news","newsList":[{"id":"2679106243","title":"智翔金泰（688443）披露2026年第三季度报告，10月30日股价上涨1.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2679106243","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679106243?lang=zh_cn&edition=full","pubTime":"2026-10-30 22:59","pubTimestamp":1793372374,"startTime":"0","endTime":"0","summary":"近日，重庆智翔金泰生物制药股份有限公司披露《2026年第三季度报告》。公告显示，本报告期营业收入为624,704,359.37元，同比增长285.23%；年初至报告期末营业收入为777,806,025.56元，同比增长274.75%。本报告期研发投入合计为91,805,531.83元，同比下降29.39%；年初至报告期末研发投入合计为333,715,356.54元，同比下降4.48%。本报告期末总资产为3,021,511,958.45元，较上年度末增长0.94%；归属于上市公司股东的所有者权益为1,608,093,777.27元，较上年度末增长1.47%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026103000058203.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688443"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679089214","title":"智翔金泰：第三季度净利3.1亿元 同比扭亏为盈","url":"https://stock-news.laohu8.com/highlight/detail?id=2679089214","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679089214?lang=zh_cn&edition=full","pubTime":"2026-10-30 20:58","pubTimestamp":1793365119,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0239","688443"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679213854","title":"智翔金泰(688443)9月30日股东户数1.25万户，较上期减少5.42%","url":"https://stock-news.laohu8.com/highlight/detail?id=2679213854","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679213854?lang=zh_cn&edition=full","pubTime":"2026-10-30 19:13","pubTimestamp":1793358800,"startTime":"0","endTime":"0","summary":"证券之星消息，近日智翔金泰披露，截至2026年9月30日公司股东户数为1.25万户，较6月30日减少716.0户，减幅为5.42%。在生物制品行业个股中，智翔金泰股东户数低于行业平均水平，截至9月30日，生物制品行业平均股东户数为3.67万户。从股价来看，2026年6月30日至2026年9月30日，智翔金泰区间涨幅为8.82%，在此期间股东户数减少716.0户，减幅为5.42%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026103000046751.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688443"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679450296","title":"智翔金泰(688443.SH)发布前三季度业绩，归母净亏损638.35万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2679450296","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679450296?lang=zh_cn&edition=full","pubTime":"2026-10-30 17:18","pubTimestamp":1793351936,"startTime":"0","endTime":"0","summary":"智通财经APP讯，智翔金泰(688443.SH)发布2026年第三季度报告，公司前三季度实现营业收入7.78亿元，同比增长274.75%;归属于上市公司股东的净亏损638.35万元;归属于上市公司股东的扣除非经常性损益的净亏损1910.51万元;基本每股收益-0.02元。前三季度，公司营业收入同比增长主要系公司确认GR1803注射液授权许可协议的合同履约义务所对应的授权许可收入5.19亿元，以及公司首款商业化产品赛立奇单抗注射液(金立希®)销售收入2.57亿元，较上年同期大幅增长所致。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1516161.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688443","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678480212","title":"智翔金泰（688443）10月27日主力资金净买入285.31万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2678480212","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678480212?lang=zh_cn&edition=full","pubTime":"2026-10-28 08:47","pubTimestamp":1793148462,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月27日收盘，智翔金泰报收于22.8元，下跌5.79%，换手率1.87%，成交量2.68万手，成交额6306.83万元。近5日资金流向一览见下表：智翔金泰融资融券信息显示，融资方面，当日融资买入235.02万元，融资偿还236.71万元，融资净偿还1.69万元。智翔金泰主营业务：抗体药物的研发、生产与销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102800014280.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688443"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677903692","title":"智翔金泰（688443）10月23日主力资金净买入171.34万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2677903692","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677903692?lang=zh_cn&edition=full","pubTime":"2026-10-24 08:17","pubTimestamp":1792801067,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月23日收盘，智翔金泰报收于24.11元，上涨5.38%，换手率2.25%，成交量3.22万手，成交额7469.0万元。近5日资金流向一览见下表：智翔金泰融资融券信息显示，融资方面，当日融资买入249.64万元，融资偿还514.24万元，融资净偿还264.61万元。智翔金泰主营业务：抗体药物的研发、生产与销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102400006849.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688443"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677924220","title":"智翔金泰：泰利奇拜单抗注射液慢性自发性荨麻疹适应症上市申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2677924220","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677924220?lang=zh_cn&edition=full","pubTime":"2026-10-23 20:20","pubTimestamp":1792758059,"startTime":"0","endTime":"0","summary":"智翔金泰(688443.SH)公告称，公司泰利奇拜单抗注射液(GR1802注射液)用于慢性自发性荨麻疹适应症III期临床试验达到主要终点指标，已向国家药监局药品审评中心提交新药上市申请并获得受理。该药品为国内首款申请用于慢性自发性荨麻疹适应症新药上市的IL-4Rα抗体药物。目前该药品另有成人季节性过敏性鼻炎、特应性皮炎及慢性鼻窦炎伴鼻息肉等适应症处于审评阶段。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102300041140.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688443","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675342533","title":"智翔金泰：泰利奇拜单抗注射液慢性鼻窦炎伴鼻息肉适应症上市申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2675342533","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675342533?lang=zh_cn&edition=full","pubTime":"2026-10-14 20:49","pubTimestamp":1791982183,"startTime":"0","endTime":"0","summary":"智翔金泰(688443.SH)公告称，公司泰利奇拜单抗注射液(GR1802注射液)用于慢性鼻窦炎伴鼻息肉适应症III期临床试验达到主要终点指标，已向国家药监局药审中心提交新药上市申请并获得受理。该药品为公司自主研发的重组全人源抗IL-4Rα单克隆抗体，同靶点药物仅有两款在国内获批上市。新药上市申请尚需经过审评、临床试验现场检查等环节，上市时间存在不确定性。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101400037651.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688443"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675539505","title":"智翔金泰（688443）10月13日主力资金净买入60.90万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2675539505","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675539505?lang=zh_cn&edition=full","pubTime":"2026-10-14 08:26","pubTimestamp":1791937571,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月13日收盘，智翔金泰报收于24.2元，下跌3.24%，换手率1.61%，成交量2.31万手，成交额5616.01万元。近5日资金流向一览见下表：智翔金泰融资融券信息显示，融资方面，当日融资买入395.8万元，融资偿还265.93万元，融资净买入129.87万元，连续3日净买入累计329.89万元。智翔金泰主营业务：抗体药物的研发、生产与销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101400007177.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688443"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674868344","title":"智翔金泰（688443）披露变更签字注册会计师公告，10月9日股价下跌2.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2674868344","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2674868344?lang=zh_cn&edition=full","pubTime":"2026-10-09 22:38","pubTimestamp":1791556695,"startTime":"0","endTime":"0","summary":"近日，重庆智翔金泰生物制药股份有限公司发布公告称，因原签字注册会计师张杭女士工作变动，不再担任公司2026年度审计项目签字注册会计师。信永中和会计师事务所委派安小梅女士接替其职务，继续完成公司2026年度财务报告审计工作。安小梅女士具备注册会计师资质，自2019年起在信永中和执业，近三年签署上市公司审计报告超过3家，无不良诚信记录，且不存在影响独立性的情形。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100900038641.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688443"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673638012","title":"股市必读：智翔金泰（688443）9月30日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2673638012","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2673638012?lang=zh_cn&edition=full","pubTime":"2026-10-08 02:01","pubTimestamp":1791396070,"startTime":"0","endTime":"0","summary":"截至2026年9月30日收盘，智翔金泰报收于25.3元，上涨4.81%，换手率3.91%，成交量5.6万手，成交额1.41亿元。董秘最新回复投资者： 请问803获批。公司目前有没有收到2.5亿董秘： 尊敬的投资者您好！截至2026年9月30日，公司尚未收到该笔款项，相关财务信息敬请关注公司后续披露的定期报告。交易信息汇总资金流向9月30日主力资金净流出546.96万元，占总成交额3.87%；游资资金净流入849.88万元，占总成交额6.02%；散户资金净流出302.92万元，占总成交额2.14%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026100800001087.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688443"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670409764","title":"股市必读：智翔金泰（688443）9月24日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2670409764","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670409764?lang=zh_cn&edition=full","pubTime":"2026-09-28 02:27","pubTimestamp":1790533631,"startTime":"0","endTime":"0","summary":"截至2026年9月24日收盘，智翔金泰报收于24.61元，下跌3.45%，换手率3.08%，成交量4.41万手，成交额1.1亿元。截至2026年6月30日，公司研发人员194人，研发人员占比17.12%，后续公司将根据实际需求持续完善研发团队建设。目前公司现金流稳健，各项生产经营活动均正常开展。交易信息汇总资金流向9月24日主力资金净流出466.3万元，占总成交额4.22%；游资资金净流出1016.6万元，占总成交额9.2%；散户资金净流入1482.9万元，占总成交额13.42%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092800001247.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688443"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665622653","title":"股市必读：智翔金泰（688443）9月4日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2665622653","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665622653?lang=zh_cn&edition=full","pubTime":"2026-09-07 01:03","pubTimestamp":1788714193,"startTime":"0","endTime":"0","summary":"截至2026年9月4日收盘，智翔金泰报收于23.25元，下跌1.23%，换手率2.0%，成交量2.87万手，成交额6745.0万元。截至2026年9月4日，公司已收到斯乐韦米单抗注射液上市里程碑付款，相关情况敬请您关注公司后续披露的定期报告。根据《GR1801注射液独家合作协议》，公司将获得斯乐韦米单抗注射液中国大陆区域销售收入，该部分销售收入公司将按照《企业会计准则》相关规定确认营业收入。半年度报告的营业收入未包含BD许可收入。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090700000508.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688443","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665365274","title":"每周股票复盘：智翔金泰（688443）营收增237.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2665365274","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665365274?lang=zh_cn&edition=full","pubTime":"2026-09-06 02:29","pubTimestamp":1788632949,"startTime":"0","endTime":"0","summary":"截至2026年9月4日收盘，智翔金泰报收于23.25元，较上周的24.22元下跌4.0%。本周，智翔金泰8月31日盘中最高价报24.6元。本周关注点来自业绩披露要点：报告期内，公司实现营业收入153,101,666.19元，较上年同期增长237.29%。公司公告汇总重庆智翔金泰生物制药股份有限公司2026年半年度报告摘要显示，公司代码688443，公司简称智翔金泰。2026年上半年实现营业收入15,310.17万元，同比增长237.29%；研发费用24,190.98万元，同比增长10.28%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090600000703.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688443"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663655072","title":"智翔金泰（688443）披露2026年半年度报告，8月31日股价下跌2.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663655072","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663655072?lang=zh_cn&edition=full","pubTime":"2026-08-31 18:34","pubTimestamp":1788172499,"startTime":"0","endTime":"0","summary":"截至2026年8月31日收盘，智翔金泰报收于23.68元，较前一交易日下跌2.23%，最新总市值为86.83亿元。该股当日开盘23.88元，最高24.6元，最低23.58元，成交额达8398.53万元，换手率为2.46%。公司于近日披露《2026年半年度报告》。研发投入占营业收入的比例为158.01%。总资产为2,739,111,981.25元，较上年度末下降8.49%；归属于上市公司股东的净资产为1,281,547,457.57元，较上年度末下降19.13%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083100029303.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688443","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663079098","title":"智翔金泰2026年半年报：核心产品放量营收翻倍，亏损幅度扩大","url":"https://stock-news.laohu8.com/highlight/detail?id=2663079098","media":"蓝鲸财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663079098?lang=zh_cn&edition=full","pubTime":"2026-08-31 17:49","pubTimestamp":1788169742,"startTime":"0","endTime":"0","summary":"蓝鲸新闻8月31日讯，8月30日，智翔金泰 公布2026年中报，公司依托核心产品赛立奇单抗纳入医保后的放量效应，受益于自身免疫性疾病领域商业化进程加速，报告期营收实现翻倍式增长；与此同时，公司持续保持高强度研发投入并推进多管线临床进展，虽亏损幅度有所扩大，但现金储备依然充裕，商业化与研发双轮驱动格局进一步夯实。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1788148444170794855","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK0239","688443"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663049467","title":"智翔金泰(688443)6月30日股东户数1.32万户，较上期增加2.84%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663049467","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663049467?lang=zh_cn&edition=full","pubTime":"2026-08-30 17:07","pubTimestamp":1788080878,"startTime":"0","endTime":"0","summary":"证券之星消息，近日智翔金泰披露，截至2026年6月30日公司股东户数为1.32万户，较3月31日增加365.0户，增幅为2.84%。在生物制品行业个股中，智翔金泰股东户数低于行业平均水平，截至6月30日，生物制品行业平均股东户数为3.54万户。从股价来看，2026年3月31日至2026年6月30日，智翔金泰区间跌幅为9.39%，在此期间股东户数增加365.0户，增幅为2.84%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083000011139.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688443","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663010022","title":"每周股票复盘：智翔金泰（688443）纬利妥米单抗附条件获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2663010022","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663010022?lang=zh_cn&edition=full","pubTime":"2026-08-30 04:44","pubTimestamp":1788036251,"startTime":"0","endTime":"0","summary":"截至2026年8月28日收盘，智翔金泰报收于24.22元，较上周的25.95元下跌6.67%。本周，智翔金泰8月28日盘中最高价报26.5元。本周关注点来自公司公告汇总：纬利妥米单抗注射液获国家药监局附条件批准上市。公司公告汇总自愿披露关于纬利妥米单抗注射液附条件批准上市的公告重庆智翔金泰生物制药股份有限公司收到国家药品监督管理局核准签发的《药品注册证书》，批准公司自主研发的纬利妥米单抗注射液附条件上市。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083000001441.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688443","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662704554","title":"智翔金泰：纬利妥米单抗注射液获附条件批准上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2662704554","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662704554?lang=zh_cn&edition=full","pubTime":"2026-08-27 19:33","pubTimestamp":1787830433,"startTime":"0","endTime":"0","summary":"智翔金泰(688443.SH)公告称，公司收到国家药监局核准签发的《药品注册证书》，批准自主研发的纬利妥米单抗注射液(GR1803注射液，商品名：维可妥)附条件上市。该药品适用于既往至少接受过三线治疗的复发或难治性多发性骨髓瘤成人患者。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082700046345.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688443","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661067211","title":"每周股票复盘：智翔金泰（688443）GR2302注射液获两项临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2661067211","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661067211?lang=zh_cn&edition=full","pubTime":"2026-08-23 02:54","pubTimestamp":1787424850,"startTime":"0","endTime":"0","summary":"截至2026年8月21日收盘，智翔金泰报收于25.95元，较上周的26.36元下跌1.56%。本周，智翔金泰8月20日盘中最高价报27.7元。自愿披露关于GR2302注射液慢性乙型肝炎适应症获得药物临床试验批准通知书的公告重庆智翔金泰生物制药股份有限公司收到国家药品监督管理局签发的《药物临床试验批准通知书》，其自主研发的GR2302注射液获准开展慢性乙型肝炎适应症的临床试验。截至目前，国内尚无同靶点药物获批开展临床试验。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082300000571.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688443"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1793402019942,"stockEarnings":[{"period":"1week","weight":-0.0406},{"period":"1month","weight":-0.0858},{"period":"3month","weight":0.041},{"period":"6month","weight":-0.2191},{"period":"1year","weight":-0.2209},{"period":"ytd","weight":-0.1509}],"compareEarnings":[{"period":"1week","weight":-0.0248},{"period":"1month","weight":-0.0633},{"period":"3month","weight":-0.0609},{"period":"6month","weight":-0.1248},{"period":"1year","weight":-0.0973},{"period":"ytd","weight":-0.0932}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"重庆智翔金泰生物制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"12492人(较上一季度减少5.42%)","perCapita":"11478股","listingDate":"2023-06-20","address":"重庆市巴南区麻柳大道699号2号楼A区","registeredCapital":"36668万元","survey":" 重庆智翔金泰生物制药股份有限公司的主营业务是抗体药物的研发、生产及商业化。公司的主要产品是赛立奇单抗（GR1501）、斯乐韦米单抗（GR1801）、纬利妥米单抗（GR1803）、唯康度塔单抗（GR2001）、泰利奇拜单抗（GR1802）、GR1603、GR2301、GR2303、GR2302、GR2304、GR2502、GR2603。公司2022年11月28日获得高新技术企业认定证书。","listedPrice":37.88},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.1","shortVersion":"4.52.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"智翔金泰-U(688443)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供智翔金泰-U(688443)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"智翔金泰-U,688443,智翔金泰-U股票,智翔金泰-U股票老虎,智翔金泰-U股票老虎国际,智翔金泰-U行情,智翔金泰-U股票行情,智翔金泰-U股价,智翔金泰-U股市,智翔金泰-U股票价格,智翔金泰-U股票交易,智翔金泰-U股票购买,智翔金泰-U股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"智翔金泰-U(688443)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供智翔金泰-U(688443)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}